| Popis: |
Patients who have increased systemic vascular resistance together with decreased cardiac output are ideal candidates for vasodilator therapy. Due to its high vascular specificity, nisoldipine, a relatively new dihydropyridine derivative [1, 2], has raised hopes as to its beneficial effect in patients with congestive heart failure of ischemic origin. Nisoldipine is pharmacologically active in low doses, and in clinical use it is virtually free of any unwanted depressant effect on myocardial contractility, while its highly selective action on vascular smooth muscle results in a reduction in afterload with a simultaneous increase in myocardial blood supply. In the present study the efficacy and tolerance of nisoldipine were compared with those of isosorbide dinitrate (ISDN) on a chronic treatment schedule. |
